PIK3CA mutation status, progression and survival in advanced HR +/HER2-breast cancer: a meta-analysis of published clinical trials

Fillbrunn, M; Signorovitch, J; Andre, F; Wang, I; Lorenzo, I; Ridolfi, A; Park, J; Dua, A; Rugo, HS

Signorovitch, J (通讯作者)，Anal Grp Inc, Boston, MA 02199 USA.

BMC CANCER, 2022; 22 (1):

Abstract

Background Approximately 40% of hormone receptor positive/human epidermal receptor 2 negative (HR + /HER2-) metastatic breast cancer (mBC) patients ha......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索